Piramal Pharma to end Bayer distribution deal in 2026

Piramal Pharma Ltd announced that its commercial arrangement with Bayer Pharmaceuticals Private Limited for sales and distribution support services will expire on December 31, 2026, and will not be renewed. The arrangement, which primarily involved commission-based income for Piramal Pharma, accounts for less than 5% of the company's consolidated revenue. Piramal Pharma is working with Bayer to ensure a smooth transition. The company does not expect the non-renewal to materially impact its profitability or financial position due to the commission-based nature of the income and its small contribution to overall revenue.